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Abstract: The anti-inflammatory action of silver nanoparticles (NPs) has been reported in 
a murine model of asthma in a previous study. But more specific mechanisms of silver NPs 
in an attenuation of allergic airway inflammation have not yet been established. Vascular and 
mucous changes are believed to contribute largely in pathophysiology in asthma. Among 
various factors related to vascular changes, vascular endothelial growth factor (VEGF) plays 
a pivotal role in vascular changes in asthma. Mucin proteins MUC5AC and MUC5B have 
been implicated as markers of goblet cell metaplasia in lung pathologies. The aim of this 
study was to investigate the effects of silver NPs on VEGF signaling pathways and mucus 
hypersecretion. Ovalbumin (OVA)-inhaled female BALBc mice were used to evaluate the 
role of silver NPs and the related molecular mechanisms in allergic airway disease. In this 
study, with an OVA-induced murine model of allergic airway disease, it was found that the 
increased levels of hypoxia-inducible factor (HIF)-1α, VEGF, phosphatidylinositol-3 kinase 
(PI3K) and phosphorylated-Akt levels, and mucous glycoprotein expression (Muc5ac) in lung 
tissues were substantially decreased by the administration of silver NPs. In summary, silver NPs 
substantially suppressed mucus hypersecretion and PI3K/HIF-1α/VEGF signaling pathway in 
an allergic airway inflammation.
Keywords: allergic airway disease, hypoxia inducible factor-1α, vascular endothelial growth 
factor
Introduction
Airway remodeling is a multifactorial process that involves complex interactions 
among cytokines, growth factors, and cell adhesion molecules, which can then 
influence epithelial cells and smooth-muscle cells of the airway as well as vascular-
ization and mucus production.1 Allergic inflammation imposes several functional 
and structural changes on blood vessels in the respiratory tract; these include vaso-
dilation, increased blood flow, angiogenesis, and increased vascular permeability 
of asthmatic airways. However, little is known about the functional significance of 
bronchial vascular remodeling in asthma. These changes may affect recruitment 
of inflammatory cells, hyperresponsiveness of airway, and regulation of airway 
caliber, as well as the level of disease control. Vascular endothelial growth factor 
(VEGF) plays a pivotal role in vascular remodeling and angiogenesis. Elevated 
VEGF levels have been observed in tissues and biological samples from individu-
als with asthma.2 Moreover, the VEGF level in asthmatic subjects correlates closely 
with disease activity, and correlates inversely with the dimension of airway caliber. 
Peribronchovascular angiogenesis is believed to contribute to airway narrowing 
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and edema, which further augment airway obstruction in 
asthma. VEGF, also known as a vascular permeability factor, 
increases vascular permeability, allowing plasma proteins to 
leak into extravascular spaces. The plasma protein leakage 
induces a thickened, engorged, and edematous airway wall, 
resulting in narrowing of the airway lumen and profound 
alterations of the endothelial cell matrix.3 Overexpression 
of VEGF in airways of transgenic mice promotes angiogen-
esis as expected, but it also induces allergic inflammation, 
enhanced allergic sensitization, upregulation of subsequent 
T helper (Th)-2-type inflammatory responses, and mucous 
gland hyperplasia.4
Widespread airway mucus plugging has long been 
recognized as a central cause of death from asthma.5 This 
finding has been repeatedly confirmed,6 and a recent quan-
titative study of fatal asthma found that more than 98% of 
airways were occluded because of mucus.7 However, the 
effect of mucus hypersecretion on the symptoms, signs, and 
pathophysiology of less severe asthma subjects is still part of 
ongoing investigations. The effect of mucus hypersecretion 
on airflow obstruction in nonfatal asthma subjects has not yet 
been compared with the effects of other causes for airway 
closure such as extravasated plasma and airway narrowing 
from smooth-muscle contraction.8 Mucin protein MUC5B 
is the principal gel-forming mucin produced and secreted in 
small airways under healthy conditions, and MUC5AC is the 
principal gel-forming mucin upregulated during asthmatic 
inflammation.
Nanomaterials are a diverse class of extremely small 
(,100 nm) substances, formed by molecular engineering 
and designed to offer unique mechanical, optical, electrical, 
and magnetic properties.9 Recently, much effort has been 
devoted to the development of biomedical applications, such 
as drug delivery, for nanoparticles (NPs) because they are 
able to pass readily through cell membranes.10 Metal NPs 
have attracted attention owing to their important applica-
tions in a number of areas, such as catalysis and nanoscale 
electronics.11 Over the past couple of decades, noble metal 
NPs have been the subject of intense research for use in 
biomedicine.12,13 Some noble metal NPs are catalysts for 
reduction reactions; and thus, may be usable as antioxi-
dants, to reduce reactive oxygen species (ROS) in the living 
body.14–16 Another candidate material for NPs is silver, which 
acts as a strong antimicrobial agent and disinfectant, pos-
sibly due to its ability to block respiratory enzyme pathways, 
alter microbial DNA, and modify cell walls.17 Silver NPs 
have been shown to block the proliferation and migration 
of endothelial cells.18
Some studies of silver NPs have demonstrated their 
cytoprotective activities toward human immunodeficiency 
virus-1-infected cells and their anti-inflammatory effects, 
through cytokine modulation upon topical application.19,20 The 
exact mechanisms of their anti-inflammatory effects are not 
fully understood. The authors of this present study previously 
reported the antioxidant and anti-inflammatory effects of sil-
ver NPs in an allergen-induced asthmatic animal model.21
In this present study, the authors hypothesize that silver 
NPs control the VEGF signaling pathway and mucin regula-
tion in asthmatic airway inflammation.
Materials and methods
Animals and experimental protocol
Female BALBc mice, 8–10 weeks of age and free of murine-
specific pathogens, were obtained from Damul Science Inc, 
(Daejeon, South Korea) and were maintained under standard 
laboratory conditions in a pathogen-free cage, with ad-libitum 
access to food and water. All animal experiments in this 
study were conducted in accordance with the guidelines 
of the Institutional Animal Care and Use Committee of the 
Chungnam National University Medical School.
Mice were sensitized on days 1 and 14 via an intraperi-
toneal injection of 20 µg ovalbumin (OVA) (Sigma-Aldrich, 
St Louis, MO) emulsified in 1 mg of aluminum hydroxide 
(Pierce Chemical Co, Rockford, IL) in a total volume of 
100 µL. On days 21–23 after the initial sensitization, the 
mice were challenged for 30 minutes with an aerosol of 
3% (weight/volume) OVA in saline (or saline alone as a 
control) using an ultrasonic nebulizer (NE-U12; Omron 
Co, Tokyo, Japan). Bronchoalveolar lavage (BAL) was 
performed 48 hours after the final challenge. At the time 
of lavage, the mice (8 per group) were sacrificed with an 
overdose of pentobarbital sodium (100 mg/kg bodyweight, 
intraperitoneally). The chest cavity was exposed to allow for 
expansion, after which the trachea was carefully intubated 
and the catheter was secured with ligatures. Pre-warmed 
0.9% NaCl solution was slowly infused into the lungs and 
withdrawn. The aliquots were pooled and kept at 4°C. A part 
of each pool was centrifuged, and the supernatant was kept 
at −70°C until use. Total cell numbers were counted using a 
hemocytometer. Smears of BAL cells were prepared using a 
cytospin (Cellspin; Hanil Science Industrial Co, Ltd, Inchon, 
South Korea). To examine cell differentials, the smears were 
stained with Diff-Quik solution (Dade Diagnostics of PR Inc, 
Aguada, Puerto Rico). Two independent, blinded investiga-
tors counted the cells under a microscope. Approximately 
400 cells were counted in each of four random locations. 
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The inter-investigator variation was ,5%, and the mean 
number of cells from both counts was used to estimate cell 
differentials.
Cell culture
The human umbilical vascular endothelial cells (HUVECs) 
were purchased from American Type Culture Collection 
(Rockville, MD). HUVECs were cultured in cell growth 
medium-2 (Lonza, Walkersville, MD) per manufacturer’s 
recommendations on 2% gelatin-coated dishes. HUVECs 
were cultured between passages 2–8 at 37°C in a humidified 
incubator with 5% (volume/volume) CO2. The cells were pas-
saged when they approached 80% confluence with trypsin/
EDTA (Lonza) to provide maintenance cultures on 10 cm2 
culture dishes. Cells were washed with phosphate-buffered 
saline and serum-starved in endothelial cell basal medium-2 
(Lonza) for 48 hours prior to assays.
Measurements of silver NPs
Silver NPs were obtained from Nano Chemical Inc, 
(  SilvergenTM, Daejeon, South Korea). For physicochemical 
studies (Table 1) of silver NPs, assistance was provided from 
the National Nanofab Center, Korea Advanced Institute of 
Science and Technology in Daejeon. Transmission electron 
microscopy (TEM) was performed by fixation on a Formvar 
carbon-coated copper grid (200 mesh) using an alcohol for 
prevention of aggregating particles and elimination of water. 
Primary particle size was measured using a transmission 
electron microscope (JEM-3020, 300 kV; JEOL, Tokyo, 
Japan). To enable the characterization of the samples using 
TEM imaging with a reasonable resolution, a solution of 
silver NPs was diluted in alcohol and was dispersed evenly 
for prevention of aggregating particles and elimination of 
water. Particles were spherical. The diameter measurements 
were performed at random. Mean surface area and number 
of particles were calculated based on mass concentration and 
average TEM diameter. In addition, the size and the size dis-
tribution (see Supplementary material) of the silver NPs were 
measured using a particle size analyzer (Nanotrac, Microtrac 
Inc, Largo, FL). NP size distribution was   determined for the 
synthesized samples by diluting samples in deionized water 
to approximately 1 OD and quantified using a zetasizer (Zeta-
sizer NANO-ZS, Malvern Instruments Ltd, Malvern, UK). 
Hydrodynamic diameter was calculated based on the average 
of 10 runs of the intensity weighted Z-average performed at 
25 using the cumulative fit function performed in triplicate.
Administration of silver NPs or SU5614
Silver NPs were dissolved in phosphate-buffered saline and 
administered by nebulizer (20 ppm, 40 mg/kg bodyweight/
day) five times to each animal at 24-hour intervals for 5 days 
prior to each challenge day (days 20–24), beginning 1 hour 
before the first challenge. VEGF receptor tyrosine kinase 
inhibitor SU5614 (Calbiochem-Novabiochem, San Diego, 
CA), diluted with dimethylsulfoxide (2.5 mg/kg) was admin-
istered intraperitoneally (three times, 100 µL each), five 
times to each animal at 24-hour intervals for 5 days prior to 
each challenge day (days 20–24), beginning 1 hour after the 
first challenge.
For in-vitro studies, silver NPs were administered for 
48 hours with different doses (10, 20, 50, 100, 200, or 
500 µM).
Determination of airway responsiveness
Airway responsiveness was evaluated 24 hours after the final 
challenge, with the mice in an unrestrained conscious state. 
The mice were placed in a barometric plethysmographic 
chamber (All Medicus Co, Seoul, South Korea), and baseline 
readings were taken and averaged for 3   minutes.   Increasing 
concentrations (from 2.5 to 25 mg/mL) of aerosolized 
methacholine were nebulized through an inlet into the main 
chamber for 3 minutes. Readings were taken and averaged 
for 2 minutes after each nebulization. Enhanced pause (Penh) 
was used as a measure of airway responsiveness to methacho-
line. Penh is a dimensionless value that represents a function 
of the proportion of maximal expiratory to maximal inspira-
tory box pressure signals and a function of the timing of 
expiration. It was calculated according to the manufacturer’s 
protocol as: Penh = (expiratory time/relaxation time − 1) × 
(peak expiratory flow/peak inspiratory flow). The results are 
expressed as the increase in Penh following challenge with 
each concentration of methacholine, where the baseline Penh 
(after saline challenge) is defined as 1.
Western blot analysis
Cells or lung tissues were homogenized in the presence 
of protease inhibitors, and protein concentrations were 
Table 1 Physicochemical characteristics of silver nanoparticles
TEM diameter (nm ± 1 SD) 6.0 ± 0.29
DLS size (nm ± PDI width) 24.7 ± 0.235
Crystalline structure Amorphous
Zeta potential (mV ± 1 SD) 88.67 ± 0.253
Mass concentration (mg/L) 10,100
Mean particle surface area (nm2/particle) 0.11 × 103
Abbreviations: DLS, dynamic light scattering; PDI, polydispersity index; SD, standard 
deviation; TEM, Transmission electron microscopy.
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  determined using the Bradford assay (Bio-Rad Laboratories 
Inc,   Hercules, CA). Samples were loaded onto a gel and 
  subjected to sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis at 120 V for 90 minutes. The separated 
proteins were transferred to nitrocellulose membranes (GE 
Healthcare Bio-Sciences, Piscataway, NJ) via the wet   transfer 
method (250 mA, 90 minutes). Nonspecific sites on the 
membranes were blocked by incubation for 1 hour in 5% 
nonfat dry milk in Tris-buffered saline (TBS) containing 
Tween® 20 (TBS-T) (25 mmol/L Tris, pH 7.5, 150 mmol/L 
NaCl, 0.1% Tween 20), and the blots were then incubated 
overnight at 4°C with an anti-interleukin (IL)-4 antibody 
(Serotec Ltd, Oxford, UK), anti-IL-5 antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA), anti-IL-13 antibody (R&D 
Systems, Inc, Minneapolis, MN), anti-hypoxia-inducible 
factor (HIF)-1α antibody (Santa Cruz Biotechnology), anti-
HIF-1β antibody (Cell Signaling Technology Inc, Danvers, 
MA), anti-VEGF antibody (Santa Cruz Biotechnology), anti-
Akt1 antibody (Ser473,   Epitomics Inc, Burlingame, CA), 
or anti-  phosphorylated Akt1 (p-Akt) antibody (Epitomics 
Inc,), anti-phosphatidylinositol 3-kinase (PI3K) p85 antibody 
(Millipore, Bedford, MA), anti-epidermal growth factor 
receptor (EGFR) antibody (Cell Signaling   Technology), 
and   anti-Muc5ac antibody (Thermo Fisher Scientific Inc, 
Fremont, CA). Anti-rat or anti-mouse horseradish peroxidase-
conjugated immunoglobulin G (IgG) was used to detect anti-
body   binding. The membranes were stripped and re-probed 
with an anti-actin antibody (Sigma-Aldrich) to verify equal 
loading of proteins in each lane. Specific antibody binding 
was visualized by exposure of the membranes to photographic 
film, after   treatment with enhanced   chemiluminescence 
system reagents (GE Healthcare Bio-Sciences).
Histological image analysis
For histological analysis, the mice were sacrificed 48 hours 
after the final challenge, and the lungs and trachea were filled 
with fixative (0.8% formalin, 4% acetic acid). The trachea 
was ligated, and the lungs and trachea were dissected out. 
The lung tissues were fixed with 10% (volume/volume) 
neutral-buffered formalin. Specimens were dehydrated and 
embedded in paraffin, and 4-µm-thick sections were cut using 
a Leica model 2165 rotary microtome (Leica Microsystems 
Nussloch GmbH, Nussloch, Germany). The sections were 
placed on slides, deparaffinized, and stained sequentially 
with hematoxylin 2 and eosin-Y (Richard-Allan Scientific, 
Kalamazoo, MI) or periodic acid-schiff (PAS) stain. All 
stained slides were evaluated via light microscopy under 
identical conditions with respect to magnification (20×), 
gain, camera position, and background illumination.22 For 
immunohistochemistry analysis, the sections of specimens 
were dewaxed, rehydrated, then washed three times with 
phosphate-buffered saline (pH 7.0). Sections were placed in 
boiling citrate buffer, pH 6.0, for 25 minutes and then cooled 
with cold water for 3 minutes. These sections were rinsed in 
1× TBS (pH 7.6), 5 minutes each and incubated with H2O2 
for 10 minutes at room temperature, blocked in protein block 
(Dako A/S, Glostrup, Denmark) solution for 20 minutes, 
and followed by reaction with an affinity-purified rabbit 
  polyclonal Muc5ac IgG (Thermo Fisher Scientific Inc,) as a 
primary antibody overnight at 4°C as 1:100 using Antibody 
Diluent (Dako A/S). After reaction with antibody, sections 
were washed twice in TBS-T (pH 7.6) buffer for 5 minutes 
each. Sections were incubated sequentially with peroxidase-
conjugated secondary antibodies and washed twice in TBS-T 
(pH 7.6) buffer for 5 minutes each. Slides were visualized 
with EnvisionTM Dual Link Advanced System (Dako A/S) and 
counterstained using a hematoxylin (Dako A/S). Slides were 
then dehydrated through an ascending ethanol series, cleared 
briefly in xylene, and mounted using Permount.
Densitometric analysis and statistics
All immunoreactive signals were scanned and densitometric 
analyses were performed using a Gel-Pro Analyzer (Media 
Cybernetics, Silver Spring, MD). Data are expressed as the 
mean ± standard error of the mean. Statistical comparisons 
were made using one-way analysis of variance followed by 
Scheffe’s test. Significant differences between two groups 
were determined using an unpaired Student’s t-test. Statistical 
significance was set at P , 0.05.
Results
Effect of silver NPs on cellular changes 
in BAL fluids and lung inflammation of 
OVA-sensitized and OVA-challenged mice
The numbers of total cells and eosinophils in BAL flu-
ids were increased significantly at 48 hours after OVA 
  inhalation,   compared with the cell counts after saline inhala-
tion   (Figure 1). The administration of silver NPs or SU5614 
blocked the increase in cell counts after OVA inhalation. 
Similarly, peribronchial and perivascular inflammation were 
increased significantly at 48 hours after OVA inhalation, 
compared with that after saline inhalation (Figure 1B and E). 
Peribronchial and perivascular inflammation after OVA 
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after OVA inhalation, compared with the levels after saline 
inhalation (Figure 2).
Effect of silver NPs on upstream  
and downstream molecules  
of the VEGF signaling pathway
By Western blot analysis, VEGF was shown to be constitu-
tively overexpressed in OVA-sensitized and OVA-challenged 
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Figure 1 Effect of silver NPs on bronchial inflammation in ovalbumin-sensitized 
and ovalbumin-challenged mice. Sampling was performed 48 hours after the final 
challenge  in  saline-inhaled  mice  administered  saline  (SAL),  saline-inhaled  mice 
administered 40 mg/kg of silver NPs (Ag40) or SU5614 (SU5614), ovalbumin-inhaled 
mice administered saline (OVA), and ovalbumin-inhaled mice administered 40 mg/kg 
of silver NPs (OVA+Ag40) or SU5614 (OVA+SU5614). (A) The number of total 
and differential cellular components of BAL fluids. Bars indicate the mean ± standard 
error of the mean for eight mice per group in four to six independent experiments. 
(B–G) Representative of H&E-stained sections of the lungs.
Notes: *P , 0.05 versus OVA; #P , 0.05 versus SAL. Bars indicate scale of 50 µm.
Abbreviations:  BAL,  bronchoalveolar  lavage;  H&E,  hematoxylin  and  eosin;   
NP, nanoparticle.
  inhalation was significantly decreased with the administration 
of silver NPs or SU5614 (Figure 1F and G).
Effect of silver NPs on IL-4, IL-5, and 
IL-13 expression in lung tissues of OVA-
sensitized and OVA-challenged mice
Western blot analysis revealed that IL-4, IL-5, and IL-13 
levels were increased substantially in lung tissues at 48 hours 
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Figure 2 Effect of silver NPs on IL-4, IL-5, and IL-13 expression in lung tissues 
collected from ovalbumin-sensitized and ovalbumin-challenged mice. Sampling was 
performed 48 hours after the final challenge in saline-inhaled mice administered saline 
(SAL), saline-inhaled mice administered 40 mg/kg of silver NPs (Ag40) or SU5614 
(SU5614), ovalbumin-inhaled mice administered saline (OVA), and ovalbumin-inhaled 
mice administered 40 mg/kg of silver NPs (OVA+Ag40) or SU5614 (OVA+SU5614). 
(A) Western blot analyses of IL-4, IL-5, and IL-13 in lung tissues. (B) Quantification 
of the IL-4, IL-5, and IL-13 protein levels in (A) using Gel-Pro Analyzer. Bars indicate 
the mean ± standard error of the mean and are representative of eight independent 
experiments using different preparations of lung tissues. 
Notes: The relative protein content was calculated as the ratio of the integrated 
optical density of each protein to that of actin. *P , 0.05 versus OVA; #P , 0.05 
versus SAL.
Abbreviations: IL, interleukin; NP, nanoparticle.
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mice compared with the levels in control mice (Figure 3B 
and C). The levels of HIF-1α, which is a VEGF transcrip-
tion regulator, PI3K, and p-Akt, were increased significantly 
after OVA inhalation (Figures 3A, C, and 4). The increases 
in VEGF and its upstream and downstream signal molecules 
after OVA inhalation were decreased substantially with the 
administration of silver NPs or SU5614.
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Figure 3 Effect of silver NPs on the protein expression of HIF-1α and VEGF in lung 
tissues collected from ovalbumin-sensitized and ovalbumin-challenged mice. HIF-1α 
or VEGF was measured 48 hours after the final challenge in saline-inhaled mice 
administered saline (SAL), saline-inhaled mice administered 40 mg/kg of silver NPs 
(Ag40) or SU5614 (SU5614), ovalbumin-inhaled mice administered saline (OVA), 
and ovalbumin-inhaled mice administered 40 mg/kg of silver NPs (OVA+Ag40) or 
SU5614 (OVA+SU5614). (A) Western blot analyses of HIF-1α and HIF-1β from lung 
tissues. (B) Western blot analyses of VEGF from lung tissues. (C) HIF-1α and VEGF 
protein levels in A and B, respectively, were quantified using a Gel-Pro Analyzer 
and plotted as the integrated optical density, using Microsoft Excel. Densitometric 
analyses are presented as the relative ratio of each molecule to HIF-1β or actin. 
Notes: Bars indicate the mean ± standard error of the mean and are representative 
of eight independent experiments using different preparations of total lung extracts. 
*P , 0.05 versus OVA; #P , 0.05 versus SAL.
Abbreviations: HIF, hypoxia-inducible factor; NP, nanoparticle; VEGF, vascular 
endothelial growth factor.
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Figure 4 Effect of silver NPs on the protein expression of PI3K and Akt levels 
in lung tissues collected from ovalbumin-sensitized and ovalbumin-challenged mice. 
PI3K or Akt was measured 48 hours after the final challenge in saline-inhaled mice 
administered saline (SAL), saline-inhaled mice administered 40 mg/kg of silver NPs 
(Ag40) or SU5614 (SU5614), ovalbumin-inhaled mice administered saline (OVA), 
and ovalbumin-inhaled mice administered 40 mg/kg of silver NPs (OVA+Ag40) or 
SU5614  (OVA+SU5614).  (A)  Western  blot  analyses  of  PI3K  from  lung  tissues.   
(B) Western blot analyses of phosphorylated-Akt protein levels from lung tissues. 
(C) phosphorylated-Akt levels were quantified using a Gel-Pro Analyzer and plotted 
as the integrated optical density, using Microsoft Excel. Densitometric analyses are 
presented as the relative ratio of each molecule to total Akt. 
Notes: Bars indicate the mean ± standard error of the mean and are representative 
of eight independent experiments using different preparations of total lung extracts. 
*P , 0.05 versus OVA; #P , 0.05 versus SAL.
Abbreviations:  NP,  nanoparticle;  p-AKT,  phosphorylated-Akt;  PI3K,  phosphati-
dylinositol-3 kinase; T-AKT, total Akt.
Dose-dependent effect of silver NPs  
on the protein expression of VEGF  
and its upstream and downstream  
molecules in HUVECs
To determine whether the silver NPs are closely involved 
and have a dose-dependent effect in the VEGF signaling 
pathway, Western blot analyses of the expressions of HIF-1α, 
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VEGF, and PI3K in HUVECs were performed. The levels 
of HIF-1α, VEGF, and PI3K were identified at 48 hours 
in HUVECs. Elevated HIF-1α, VEGF, and PI3K levels in 
HUVECs were found to be significantly decreased dose-
dependently   (Figure 5). The levels of  HIF-1α, VEGF, and 
PI3K levels are significantly decreased at the dose of 100, 
200, and 500 µm silver NPs. Similarly, the elevated levels of 
those proteins were substantially reduced by the administra-
tion of SU5614.
Effect of silver NPs on mucus 
hypersecretion in lung tissues from  
OVA-sensitized and OVA-challenged mice
To  investigate  the  effect  of  silver  NPs  on  mucus 
hypersecretion, a PAS stain was performed. Substantial 
mucus production was induced in OVA-sensitized and 
OVA-challenged mice with increased PAS-stained mucins 
in epithelial goblet cells. This increase was reduced sub-
stantially by the administration of silver NPs or SU5614 
(Figure 6). Also investigated was whether silver NPs could 
reduce protein levels of Muc5ac in mice. Western blot 
analysis showed significantly increased levels of Muc5ac in 
total protein extracts from lung tissues of mice at 48 hours 
after OVA inhalation, compared with the levels in control 
mice. This increase in Muc5ac after OVA inhalation was 
significantly decreased with the administration of silver 
NPs or SU5614 (Figure 7).
Immunohistochemical staining showed the localization 
of immunoreactive Muc5ac in goblet cells of the bronchial 
epithelial cell layers of OVA-sensitized and OVA-  challenged 
mice. The immunostaining of Muc5ac in goblet cells after 
OVA inhalation was decreased substantially after the admin-
istration of silver NPs or SU5614 (Figure 6).
Effect of silver NPs on EGFR expression 
in lung tissues of OVA-sensitized  
and OVA-challenged mice
By Western blot analysis, EGFR was shown to be constitu-
tively overexpressed in OVA-sensitized and   OVA-challenged 
mice compared with the levels in control mice (Figure 8). 
This increase in EGFR expression after OVA inhalation was 
substantially decreased with the administration of silver NPs 
or SU5614.
Effect of silver NPs on airway 
hyperresponsiveness
Airway responsiveness was assessed based on an increase 
in Penh in response to increasing doses of methacholine. 
In OVA-sensitized and OVA-challenged mice, the Penh 
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Figure  5  Dose-dependent  effect  of  silver  NPs  and  effect  of  SU5614  on  PI3K, 
HIF-1α, and VEGF levels in HUVECs. Expression of PI3K, HIF-1α, or VEGF protein 
was examined by immunoblot analysis. Starved cells were treated with 10, 20, 50, 
100, 200, or 500 µM silver NPs or SU5614 for 48 hours. Blots were stripped and 
reprobed for actin as a loading contol.
Abbreviations: CONT, control; HIF, hypoxia-inducible factor; NP, nanoparticle; 
PI3K, phosphatidylinositol-3 kinase; VEGF, vascular endothelial growth factor.
A D
E B
CF
Figure 6 Effect of silver NPs and SU5614 on mucus production in OVA-sensitized 
and OVA-challenged mice. Histological examination was obtained from lung tissue 
48 hours after the final challenge in saline-inhaled mice administered saline (A), saline-
inhaled mice administered 40 mg/kg of silver NPs (B), or SU5614 (C), OVA-inhaled mice 
administered saline (D), OVA-inhaled mice administered 40 mg/kg of silver NPs (E), or 
SU5614 (F). Paraffin section slide of lung tissues were stained periodic acid-schiff stain.
Notes:  All  stained  slides  were  evaluated  via  light  microscopy  under  identical 
conditions with respect to magnification (20×), gain, camera position, and background 
illumination. Bars indicate 50 µm.
Abbreviations: NP, nanoparticle; OVA, ovalbumin.
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dose–response curve was shifted to the left compared with 
the control curve (Figure 9). In addition, Penh produced 
by the administration of methacholine at 25 mg/mL was 
significantly greater in OVA-inhaled mice than in control 
mice. OVA-sensitized and OVA-challenged mice treated 
with silver NPs or SU5614 showed a substantial reduction 
in methacholine (25 mg/mL) – induced Penh compared with 
untreated mice after OVA inhalation. These results indicate 
that silver NP or SU5614 treatment reduces OVA-induced 
airway hyperresponsiveness.
Discussion
The authors of this present study have previously demon-
strated that silver NPs have negative effects in pulmonary 
Th-2 inflammation and airway hyperresponsiveness and in 
nuclear factor (NF)-κB nuclear translocation and attenuation 
Muc5ac
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OVA+SU5614
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Figure 7 Effect of silver NPs and SU5614 on the protein expression of Muc5ac 
in lung tissues collected from ovalbumin-sensitized and ovalbumin-challenged mice. 
(A) Western blot analyses of Muc5ac in total protein extracts from lung tissues. 
(B–G) Localization of immunoreactive Muc5ac in the bronchiolar epithelial layer. 
Muc5ac  was  measured  48  hours  after  the  final  challenge  in  saline-inhaled  mice 
administered saline (SAL or B), saline-inhaled mice administered silver NPs (Ag40 
or C), saline-inhaled mice administered SU5614 (SU5614 or D), ovalbumin-inhaled 
mice  administered  saline  (OVA  or  E),  ovalbumin-inhaled  mice  administered 
silver NPs (OVA+Ag40 or F), and ovalbumin-inhaled mice administered SU5614 
(OVA+SU5614 or G).
Notes: Brown color indicates Muc5ac-positive cells. Bars indicate 50 µm.
Abbreviation: NP, nanoparticle.
SAL
Ag40
SU 5614
OVA
OVA+Ag40
OVA+Su5614
EGFR
Actin
Figure 8 Effect of silver NPs and SU5614 on the protein expression of EGFR in 
lung tissues collected from ovalbumin-sensitized and ovalbumin-challenged mice. 
Western blot analysis of EGFR in total protein extracts from lung tissues. EGFR was 
measured 48 hours after the final challenge in saline-inhaled mice administered saline 
(SAL), saline-inhaled mice administered 40 mg/kg of silver NPs (Ag40) or SU5614 
(SU5614), ovalbumin-inhaled mice administered saline (OVA), and ovalbumin-inhaled 
mice administered 40 mg/kg of silver NPs (OVA+Ag40) or SU5614 (OVA+SU5614). 
Blots were stripped and reprobed for actin as a loading contol.
Abbreviations: EGFR, epidermal growth factor receptor; NP, nanoparticle.
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Figure 9 Effect of silver NPs on airway responsiveness to inhaled methacholine 
in ovalbumin-sensitized and ovalbumin-challenged mice. Airway hyperresponsiveness 
was measured at 24 hours after the final challenge in saline-inhaled mice administered 
saline (SAL), saline-inhaled mice administered 40 mg/kg of silver NPs (Ag40) or SU5614 
(SU5614), ovalbumin-inhaled mice administered saline (OVA), and ovalbumin-inhaled 
mice administered 40 mg/kg of silver NPs (OVA+Ag40) or SU5614 (OVA+SU5614).
Notes: Penh values were obtained in response to increasing doses (from 2.5 to 
25 mg/mL) of methacholine. Bars indicate the mean ± standard error of the mean 
for eight mice per group in four to six independent experiments. *P , 0.05 versus 
OVA; #P , 0.05 versus SAL.
Abbreviations: NP, nanoparticle; Penh, enhanced pause.
of ROS generation as an underlying mechanism.21 In 
addition, they previously provided safety profiles for inhaled 
silver NPs. In the present study, the mechanism(s) that con-
tribute to the anti-asthmatic role of silver NPs by evaluating 
their effects on VEGF activity and Muc5ac overexpres-
sion in allergen-induced airway inflammation was further 
investigated.
VEGF is an endothelial cell-specific mitogenic peptide 
with key roles in vasculogenesis and angiogenesis.3 It also 
increases vascular permeability, allowing plasma proteins 
to leak into extravascular spaces, which leads to edema and 
profound alterations in the extracellular matrix. VEGF is a 
major determinant of pulmonary inflammation and vascular 
airway remodeling in asthma.2,4 Thus, inhibition of VEGF 
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activity presents a potential therapeutic strategy. Similar to 
the effects of SU5614, which is a potent inhibitor of VEGF 
receptor tyrosine kinase, silver NPs consistently decreased 
in the levels of VEGF protein and its upstream and down-
stream signal molecules HIF-1α and PI3K respectively, in 
the present study. Previous studies have demonstrated that 
VEGF receptor inhibitors induce VEGF activity in a murine 
model of asthma23,24 and in cancer cell lines under normoxic 
conditions.25 From many studies, sorafenib was developed as 
a receptor tyrosine kinase inhibitor and was approved by the 
United States Food and Drug Administration in 2005. It has 
been studied as a multi-kinase inhibitor that targets not only 
VEGF receptor tyrosine kinase but also other kinases such 
as Raf serine/threonine kinase.26,27 These findings indicate 
that the inhibition of VEGF receptor may affect a variety of 
signaling kinases.
HIF is a heterodimer composed of one of three subunits 
(HIF-1α, HIF-2α, or HIF-3α) and a constitutively expressed 
HIF-1β subunit (also known as the aryl hydrocarbon recep-
tor nuclear translocator subunit).28 As an oxygen-dependent 
transcriptional activator, HIF plays crucial roles in tumor-
related angiogenesis, inflammatory processes, and mam-
malian development. HIF-1α regulates VEGF transcription 
by binding to the VEGF promoter.28 Despite the central 
importance of hydroxylases in sensing oxygen tension and 
regulating HIF-1 activity, HIF-1 is also regulated in an 
oxygen-independent manner. Various signaling pathways 
are involved in the expression of HIF-1α.29 Growth factors, 
cytokines (tumor necrosis factor α and IL-1β), bacterial 
products, environmental stimuli, ROS, and other signaling 
molecules have been implicated in the control of HIF-1 
under nonhypoxic conditions.28,30–35 Recently, it was reported 
that VEGF expresses and stabilizes HIF-1α via its specific 
  receptor.36 The authors of this present study have previously 
shown that the increased VEGF expression in OVA-exposed 
mice is decreased by the inhibition of HIF-1α activation.34
VEGF-mediated signaling can occur through the PI3K/
Akt pathway.37 In the present study, Western blotting with an 
antibody to the regulatory subunit of PI3K (p85) showed that 
PI3K protein levels in lung tissues of mice were increased 
after OVA inhalation and that the increase was decreased by 
the administration of silver NPs. The current view is that PI3K 
is present as a preformed, inactive p85–p110 complex in the 
cytoplasm of resting cells, poised for activation in response 
to appropriate cues. Treatment with silver NPs was also 
associated with the inhibition of Akt phosphorylation, con-
sistent with the downregulation of PI3K signaling.   However, 
PI3K activity directly measuring phosphatidylinositol 
3,4,5-triphosphate was not observed. Exactly how silver 
NPs activate the PI3K/Akt pathway is unclear at this time, 
but data obtained in this present study suggest that silver 
NPs may post-translationally enhance PI3K expression and 
Akt phosphorylation. These observations imply that activa-
tion of the PI3K/Akt pathway is involved in the anti-VEGF 
activity of silver NPs.
The phosphorylation of some proteins can stimulate 
HIF-1α transactivation or synthesis by activating the 
  mitogen-activated protein kinase (MAPK) or PI3K   pathway.29 
In the present study, the effect of silver NPs on signaling 
upstream of HIF-1α, starting with the phosphorylation of 
EGFR, was examined. EGFR expression is upregulated in the 
airway epithelium of humans with asthma, cystic fibrosis, and 
chronic obstructive pulmonary disease.38 EGFR signaling is 
prominent during cellular stress, and EGFR induces HIF-1α 
mRNA synthesis. Downstream effectors of EGFR activation 
include p38 MAPK and extracellular signal-regulated kinase 
(ERK), which increase HIF pathway activation under nor-
moxic conditions by inducing HIF-1α mRNA synthesis.39–42 
Thus, post-EGFR signaling via at least one of the signal-
ing cascades, PI3K, ERK, or p38, activates HIF mRNA 
  production. In the present study, the expression of EGFR 
was upregulated in the lung tissues of mice, as has been well 
established in many previous asthma-related studies.43–45 
Thus, silver NPs regulate EGFR and may affect post-EGFR 
signaling molecules such as PI3K as well as HIF-1α levels in 
an allergic airway model, suggesting a possible mechanism 
of silver NPs in the regulation of allergic airways. Further 
studies are needed to confirm these findings. PI3K/Akt sig-
naling participates in multiple cellular metabolic pathways, 
particularly in cellular energy metabolism.46 Akt is the key 
signaling molecule in cell survival, proliferation, growth, and 
differentiation, and is involved in angiogenesis through the 
pro-survival function of VEGF.47 Moreover, Akt phospho-
rylation is an important event in regulating the survival of 
growth factors such as VEGF, transcription factors such as 
HIF-1α, and oncogenes.48 Small molecules that inhibit the 
VEGF tyrosine kinase receptor have been shown to have dual 
efficacy in blocking HIF-1 and the VEGF receptor pathway. 
The present study demonstrated that VEGF signaling affects 
HIF-1α levels in an allergic airway animal model, leading 
to the hypothesis that HIF-1α expression would be affected 
by blocking the VEGF signaling pathway and EGFR phos-
phorylation. To provide more specific data that silver NPs or 
SU5614 are involved in the PI-3K-HIF-1α-VEGF pathway, 
an in-vitro study was performed using HUVECs. HUVECs 
are activated by a variety of cytokines and growth factors 
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and secret various cytokines, adhesion molecules, and growth 
factors including VEGF. Western blot analyses of the expres-
sion of VEGF, HIF-1α, and PI3K (p85) were performed. 
Silver NPs or SU5614 significantly reduced the expression of 
HIF-1α, VEGF, and PI3K in HUVECs. The basal expression 
of these molecules was dose-dependently affected by silver 
NPs. Although there may be various pathways to modify 
VEGF–VEGF receptor signaling, the findings of this study 
indicate that silver NPs, at least in part, can affect VEGF 
signaling pathway in a dose-dependent manner as seen with 
the VEGF receptor tyrosine kinase inhibitor. Consistently, 
the data showed that increased PI3K levels, Akt phosphoryla-
tion, and HIF-1α expression in OVA-challenged mice were 
inhibited by the VEGF receptor tyrosine kinase inhibitor 
SU5614 and by silver NPs. These observations imply that 
the VEGF receptor is involved in PI3K/Akt activation and 
in HIF-1α expression in vitro and in vivo. Lee et al recently 
demonstrated a PI3 K-HIF-1α-VEGF signaling loop in an 
OVA-challenged murine model of asthma.49 This signaling 
cascade is important for both mechanistic understanding and 
therapeutic intervention, as VEGF is a potent stimulator of 
airway inflammation and airway remodeling in asthma.2,4,23 
Taken together, these data support the role of silver NPs in 
the PI3 K-HIF-1α-VEGF signaling loop.
In the present study, increased expression of the Muc5ac 
in lung tissues from OVA-challenged mice was also shown. 
Under pathological conditions including asthma, airway 
mucins may be produced and secreted in greatly increased 
quantities (mucus hypersecretion). This can be observed 
pathologically as an increase in intracellular mucins (mucous 
metaplasia) or as an increase in mucus in the airway lumen. 
Excessive luminal mucus can become impacted and lead to 
airway closure. The principal cells in the airway that regulate 
mucus clearance and secretion include ciliated epithelial 
cells, goblet cells, and Clara cells in the airway surface epi-
thelium, and serous cells and mucous cells in the submucosal 
glands. Young et al demonstrated that mRNA expression of 
Muc5ac, the most highly induced   gel-forming mucin in the 
airways of antigen-challenged mice, increases over the same 
time course as airway inflammation and goblet cell metaplasia 
after antigen challenge in transgenic mouse model.50
Several orthologous human and mouse genes encode 
gel-forming mucins. Four of these (MUC2, MUC5AC, 
MUC5B, and MUC6) are present in tandem as a conserved 
cluster on human chromosome 11p15 and on the syntenic 
mouse chromosome 7 F5.51 MUC19 is present on chromo-
some 12q12 in humans and 15 E3 in mice.52,53 MUC5AC 
and MUC5B have been implicated as markers of goblet 
cell metaplasia in lung pathologies based on expression 
studies in humans, animal models, and cell culture.54,55 The 
predominant species in the lung are MUC5AC and MUC5B, 
which in larger mammals are thought to be secreted from 
goblet cells in the superficial epithelium and from sub-
mucosal glands, respectively.56 Previous studies of human 
MUC5AC have shown direct relationships between pro- 
and anti-inflammatory mediators acting upon cis elements 
within the MUC5AC promoter. Two of these studies used 
in-vitro reporter assays to identify potential roles for NF-κB 
and glucocorticoid-response elements (GREs) in activation 
and repression of the MUC5AC promoter.50,57 However, it 
was demonstrated that NF-κB expression is not necessary 
for the induction of MUC5AC expression and goblet cell 
metaplasia, and the alignment of the 5′ flanking regions of 
MUC5AC orthologs does not reveal any well conserved 
NF-κB sites or GREs.57 According to previous reports, 
NF-κB is not directly involved in mediating cytokines, 
especially IL-13, or in activating MUC5AC, although 
NF-κB involved in Th-2 cytokine expression and, as such, 
may play an indirect role in mucin production. Control of 
the MUC5AC promoter derives from activation of cellular 
stress (HIF-1), damage (β-catenin/Lef1), and remodeling/
repair (TGF-β/SMAD) pathways.50
In addition, the elements within the first kb of the 5′ flank-
ing region of MUC5AC promoter respond to stimulation by 
cytokines such as IL-13 and EGF.58 Many cytokines such as 
IL-5, IL-9, and IL-17 induce mucus metaplasia and mucin 
gene expression, but IL-13 and IL-4Rα appear to be critical, 
in vivo and in vitro.59 In the present study, increased levels 
of HIF-1α and Th-2 cytokines IL-4, IL-5, and IL-13 were 
attenuated by the administration of silver NPs, suggesting that 
silver NPs may regulate mucous hypersecretion at least in 
part, via blocking HIF-1α and Th-2 cytokines. Furthermore, 
the activation of EGFR, which was shown to be upregulated 
in the lung tissues in the present and previous studies,43–45 is 
critical for the induction of Muc5ac and mucous metaplasia 
in animal models and the induction of MUC5AC in   epithelial 
cells of human airway in response to allergens, viruses, neu-
trophils, and cigarette smoke.60–65
The closure of hyperresponsive airway due to mucus 
hypersecretion has not been compared with airway closure 
and narrowing from other causes. However, the pharmaco-
logical inhibition of mucin secretion blocked increase of 
methacholine-induced airway resistance by approximately 
80% in a mouse model of allergic asthma,66 suggesting a 
major contribution of mucus hypersecretion under some 
circumstances.
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In summary, silver NPs decreased VEGF signaling 
and Muc5ac protein expression. Taken together, the pres-
ent results indicate that silver NPs have the potential to 
therapeutically suppress Muc5ac expression, EGFR levels, 
and PI3K/HIF-1α/VEGF signaling pathways in airways 
with minimal toxicity. The multifunctional or multidirec-
tional action of silver NPs may be helpful in the treatment 
of allergic asthma.
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